Transpersonal Psychology

iResearchNet

Home » Controversy of Psychedelics in Therapy

Controversy of Psychedelics in Therapy

The article on controversy of psychedelics in therapy explores the complex landscape surrounding the therapeutic use of psychedelics, examining their historical roots, current applications, and the controversies that arise from their resurgence in modern mental health treatment. Initially embraced for their potential to facilitate healing and personal growth, psychedelics experienced a decline in research and therapeutic use due to legal restrictions and societal stigma. However, recent studies have reignited interest, highlighting their efficacy in treating conditions such as PTSD, depression, and anxiety. This article delves into the ethical, legal, and regulatory challenges associated with psychedelic therapy, as well as public perceptions that continue to shape discourse in the field. By addressing these multifaceted issues, the article aims to foster informed discussion and consideration of psychedelics as a viable component of contemporary therapeutic practices.

Introduction

The therapeutic use of psychedelics has garnered significant attention in recent years, reawakening interest in substances such as psilocybin, MDMA, and LSD for their potential to treat various mental health disorders. Historically, these substances were employed in both indigenous practices and early 20th-century psychotherapy, where they were believed to facilitate profound emotional and cognitive insights (Gonzalez et al., 2019). However, the psychedelic renaissance has ignited a complex discourse surrounding their application in clinical settings, marked by debates over ethical considerations, legal frameworks, and societal acceptance. This article aims to explore the controversies surrounding the use of psychedelics in therapy, emphasizing the interplay between scientific evidence and cultural narratives.

The resurgence of psychedelic therapy has been fueled by a growing body of research indicating their efficacy in addressing treatment-resistant conditions such as post-traumatic stress disorder (PTSD), depression, and anxiety (Davis et al., 2020). Recent studies demonstrate that psychedelics may promote neuroplasticity and enhance therapeutic outcomes by allowing individuals to access deep-seated emotions and reframe their cognitive patterns (Carhart-Harris & Friston, 2019). Furthermore, the context in which psychedelics are administered—often characterized by supportive therapeutic environments—plays a critical role in the efficacy of these treatments. This context underscores the need for careful consideration of how psychedelics are integrated into established therapeutic modalities.

Despite the promising findings, significant controversies remain regarding the therapeutic use of psychedelics. Ethical concerns, such as informed consent and the potential for exploitation of vulnerable populations, complicate the implementation of psychedelic therapy (Grof, 2019). Additionally, the legal status of psychedelics continues to vary widely across jurisdictions, often hindering research and limiting access to these potentially life-changing treatments. Public perception of psychedelics, often influenced by historical stigma and misinformation, further complicates the dialogue surrounding their therapeutic potential. This article seeks to navigate these controversies, highlighting the challenges and opportunities presented by the integration of psychedelics into contemporary therapeutic practices.

Historical Context

The historical context of psychedelics in therapy is rich and complex, reflecting both ancient practices and modern scientific inquiry. Psychedelics, substances that induce altered states of consciousness, have been utilized for thousands of years across various cultures for healing and spiritual purposes. Indigenous peoples in the Americas, for example, have long employed plant-based psychedelics such as peyote and ayahuasca in ceremonial contexts, believing these substances facilitate connections with the divine and promote psychological healing (Schmidt et al., 2020). These traditional uses highlight the deep cultural significance of psychedelics as tools for enhancing self-awareness and community bonding, suggesting that their therapeutic potential has been recognized long before modern psychology.

In the mid-20th century, psychedelics began to gain attention in Western medicine, particularly during the 1950s and 1960s. Early research explored their potential in treating various psychological conditions, including alcoholism, depression, and anxiety. Notably, studies conducted by psychiatrists such as Sidney Cohen and Humphry Osmond demonstrated promising results in using LSD to alleviate symptoms of mental illness (Osmond, 1957). These investigations laid the groundwork for what became known as psychedelic therapy, where controlled doses of psychedelics were administered in therapeutic settings, often with accompanying psychotherapy. For instance, the study by Osmond and colleagues at the Saskatchewan Hospital found that LSD could produce significant reductions in anxiety among patients, marking a critical moment in the recognition of psychedelics as therapeutic agents (Osmond, 1957).

Despite these initial successes, the psychedelic movement faced significant backlash, culminating in the counterculture of the 1960s and the subsequent legal restrictions that followed. The rise of the anti-establishment movement saw the widespread recreational use of psychedelics, particularly LSD, which led to societal fears about their safety and effectiveness. By the late 1960s, growing concerns over drug abuse, safety, and the potential for psychological harm prompted governments worldwide to impose strict regulations on psychedelic substances. The Controlled Substances Act of 1970 in the United States classified LSD and other psychedelics as Schedule I drugs, effectively halting most research and therapeutic applications (Nutt et al., 2010). This legal framework created an environment where scientific exploration was stifled, and the therapeutic potential of psychedelics was largely dismissed.

The decline of psychedelic research persisted for decades, overshadowed by negative media portrayals and societal stigma. However, the late 20th century witnessed a gradual resurgence of interest in psychedelics, particularly in the 1990s and 2000s. Researchers and therapists began to advocate for the reevaluation of psychedelics as legitimate therapeutic tools, leading to a wave of new studies aimed at investigating their safety and efficacy. The Multidisciplinary Association for Psychedelic Studies (MAPS) played a pivotal role in this revival by funding research on MDMA-assisted psychotherapy for PTSD, sparking renewed interest in the therapeutic applications of psychedelics (MAPS, 2023). This resurgence has not only rekindled scientific inquiry but also led to a broader cultural shift in perceptions of psychedelics, as evidenced by the increasing number of clinical trials exploring various psychedelics, including psilocybin, ayahuasca, and ketamine.

Modern studies have demonstrated the potential of psychedelics to facilitate profound therapeutic experiences, leading to lasting improvements in mental health. Research has shown that psychedelics can promote neurogenesis, enhance emotional processing, and create a sense of interconnectedness, all of which can significantly impact therapeutic outcomes (Carhart-Harris et al., 2016). A landmark study published in 2020 found that psilocybin-assisted therapy resulted in significant reductions in depressive symptoms among participants, further legitimizing the role of psychedelics in therapeutic settings (Davis et al., 2020). These findings have opened new avenues for understanding the mechanisms through which psychedelics exert their effects, underscoring the importance of therapeutic context and integration in maximizing their potential benefits.

In conclusion, the historical context of psychedelics in therapy reflects a dynamic interplay between cultural practices, scientific exploration, and societal attitudes. From their ancient use in spiritual rituals to their exploration in modern psychotherapy, psychedelics have evolved from revered substances to restricted drugs and back to promising therapeutic agents. As research continues to expand our understanding of psychedelics and their potential applications, it is crucial to navigate the historical lessons learned while addressing the ethical, legal, and societal challenges that accompany their reintegration into therapeutic practices.

Current Research and Clinical Applications

Recent years have witnessed a significant resurgence in research exploring the therapeutic potential of psychedelics, with numerous clinical trials demonstrating their efficacy in treating various mental health disorders. This renewed interest is largely driven by advancements in neuropsychopharmacology, an increasing recognition of the limitations of conventional therapies, and a societal shift in attitudes toward psychedelics. Notable substances under investigation include psilocybin, MDMA, and ketamine, each exhibiting unique mechanisms of action and therapeutic applications.

Psilocybin

Psilocybin, the active compound found in certain mushrooms, has emerged as a leading candidate in psychedelic research. Numerous studies have highlighted its efficacy in treating depression, anxiety, and substance use disorders. A landmark trial conducted by Griffiths et al. (2016) revealed that psilocybin, combined with psychological support, resulted in significant reductions in symptoms of treatment-resistant depression. Participants reported sustained improvements in mood and quality of life, with effects lasting several months post-treatment. This study laid the groundwork for further investigations, including randomized controlled trials (RCTs) that continue to explore psilocybin’s therapeutic potential.

Another pivotal study by Davis et al. (2020) examined the effects of psilocybin-assisted therapy in patients with major depressive disorder. In this trial, participants received two doses of psilocybin in conjunction with psychotherapy, resulting in significant decreases in depressive symptoms compared to a placebo group. The researchers found that over half of the participants achieved remission by the end of the study, underscoring the potential of psilocybin as a transformative therapeutic agent. These findings have prompted the establishment of further research initiatives, including ongoing studies exploring psilocybin’s effects on end-of-life anxiety among terminally ill patients (Griffiths et al., 2020).

MDMA

MDMA (3,4-methylenedioxymethamphetamine), commonly known as “Ecstasy,” has gained traction as a promising treatment for post-traumatic stress disorder (PTSD). The Multidisciplinary Association for Psychedelic Studies (MAPS) has spearheaded research into MDMA-assisted psychotherapy, which integrates the substance with traditional therapeutic techniques. A pivotal Phase 3 trial demonstrated that MDMA, administered in a therapeutic setting, resulted in significant reductions in PTSD symptoms among participants (Mithoefer et al., 2021). The study found that approximately 67% of participants no longer met the criteria for PTSD after treatment, illustrating the profound impact of MDMA on trauma processing and emotional healing.

The mechanism by which MDMA aids in therapy is believed to involve increased feelings of trust and emotional safety, allowing patients to confront traumatic memories more effectively (Mithoefer et al., 2021). The integration of MDMA into psychotherapy sessions appears to enhance therapeutic rapport and facilitates deep emotional processing, leading to improved outcomes. These findings have led to calls for the incorporation of MDMA-assisted therapy into standard PTSD treatment protocols, with ongoing studies aimed at exploring its effectiveness in diverse populations and varying trauma contexts.

Ketamine

Ketamine, originally developed as an anesthetic, has emerged as a fast-acting antidepressant, particularly for individuals with treatment-resistant depression. Unlike traditional antidepressants, which can take weeks to show effects, ketamine’s rapid action provides a critical alternative for patients experiencing acute depressive episodes. Research has demonstrated that a single infusion of ketamine can lead to significant reductions in depressive symptoms within hours (Zanos & Gould, 2018). This rapid onset of action is especially important for individuals at risk of suicide, offering a potential lifeline in moments of crisis.

Ketamine’s unique mechanism of action involves the modulation of glutamate, a neurotransmitter associated with synaptic plasticity and mood regulation. Studies suggest that ketamine promotes neuroplasticity, facilitating the formation of new neural connections that may be impaired in depressive disorders (Duman et al., 2016). Furthermore, emerging research indicates that combining ketamine with psychotherapy enhances therapeutic outcomes, as the experience can lead to profound insights and emotional breakthroughs (Dore et al., 2021).

Integrating Psychedelics into Clinical Practice

The successful application of psychedelics in clinical settings necessitates a careful consideration of therapeutic context and integration. The setting in which psychedelics are administered plays a critical role in the overall effectiveness of treatment. Clinical trials emphasize the importance of a supportive environment, trained therapists, and structured integration sessions following psychedelic experiences (Johnson et al., 2021). Integration therapy focuses on helping patients make sense of their psychedelic experiences and incorporate insights gained into their everyday lives, thereby enhancing the overall therapeutic effect.

Moreover, as research continues to evolve, ethical considerations surrounding the administration of psychedelics in therapy become increasingly salient. Issues related to informed consent, therapeutic boundaries, and the potential for adverse effects must be carefully navigated to ensure patient safety and well-being (Grof, 2019). Establishing standardized protocols and guidelines for psychedelic therapy is essential as these substances gain acceptance within mainstream therapeutic practices.

In summary, the current landscape of research and clinical applications of psychedelics highlights their transformative potential in treating various mental health disorders. As studies continue to unveil the efficacy and safety of substances like psilocybin, MDMA, and ketamine, the integration of psychedelics into therapeutic settings promises to revolutionize mental health treatment. However, navigating the complexities of ethical considerations and therapeutic contexts remains crucial in harnessing their full potential.

Controversies and Challenges

As the therapeutic potential of psychedelics gains recognition, a host of controversies and challenges has emerged, complicating their integration into mainstream mental health treatment. These issues range from ethical considerations and legal regulations to societal perceptions and potential misuse, highlighting the need for careful navigation in the evolving landscape of psychedelic therapy.

Ethical Considerations

One of the most pressing ethical concerns surrounding the use of psychedelics in therapy is the issue of informed consent. Given the profound alterations in consciousness that psychedelics induce, ensuring that patients fully understand the risks and benefits is paramount. Many patients seeking psychedelic therapy may be vulnerable due to their mental health conditions, raising concerns about their ability to make fully informed decisions (Grof, 2019). Clinicians must be diligent in providing comprehensive information about the potential effects, both positive and negative, to empower patients to make informed choices about their treatment.

Additionally, the therapeutic setting itself can create power dynamics that may influence patient experiences and outcomes. The role of the therapist is critical, as their expertise and presence can significantly impact how patients navigate their psychedelic experiences (Bouso et al., 2018). Ethical dilemmas arise when therapists may unintentionally influence the interpretation of experiences or project their beliefs onto patients, potentially compromising the therapeutic process. Establishing clear ethical guidelines for practitioners is essential to mitigate these risks and ensure that patient autonomy and well-being remain at the forefront of psychedelic therapy.

Legal and Regulatory Issues

Legal and regulatory challenges pose significant barriers to the advancement of psychedelic therapy. While some jurisdictions have begun to relax restrictions on psychedelics, many remain classified as Schedule I substances under the Controlled Substances Act in the United States, indicating that they are perceived as having no accepted medical use and a high potential for abuse (Nutt et al., 2010). This classification creates formidable hurdles for researchers seeking to conduct clinical trials, as obtaining necessary approvals can be a lengthy and complex process.

Furthermore, the inconsistent legal status of psychedelics across different countries complicates international collaboration and research efforts. In some regions, psychedelics have been decriminalized or are being considered for therapeutic use, while in others, they remain strictly prohibited. This patchwork of regulations can lead to disparities in access to treatment, with some patients benefiting from innovative therapies while others remain unable to access potentially life-saving interventions (Friedman, 2022). Establishing a cohesive legal framework that balances public safety with the need for research and therapeutic application is essential for advancing the field of psychedelic therapy.

Public Perception and Stigma

Public perception of psychedelics is another significant challenge that influences the discourse surrounding their therapeutic use. The historical context of psychedelics, particularly their association with counterculture movements and recreational use, has contributed to enduring stigma (Harrison et al., 2021). Many individuals still associate psychedelics with irresponsible behavior or harmful effects, leading to skepticism about their use in clinical settings. This stigma can hinder patients from seeking psychedelic therapy and may discourage healthcare providers from incorporating these treatments into their practices.

Efforts to reframe the narrative surrounding psychedelics are crucial in addressing this stigma. Public education campaigns highlighting the scientific evidence supporting the safety and efficacy of psychedelics in therapy can help shift perceptions and foster acceptance. Moreover, the portrayal of psychedelics in popular media, which often sensationalizes their use, can perpetuate misconceptions and hinder progress (Zhang et al., 2020). Engaging with diverse communities to promote accurate information and understanding can pave the way for broader societal acceptance of psychedelic therapy.

Risk of Misuse and Dependency

While the therapeutic use of psychedelics is grounded in careful administration and support, the potential for misuse and dependency remains a concern. As psychedelics gain popularity, there is a risk that individuals may seek to use them outside of controlled therapeutic settings, leading to adverse outcomes. Recreational use of psychedelics can result in dangerous situations, particularly for those with underlying mental health conditions (Friedman, 2022). The lack of established protocols for self-administration heightens the risk of negative experiences and psychological harm.

To mitigate these risks, establishing guidelines for safe use, education on responsible practices, and access to support systems for individuals using psychedelics outside clinical settings is essential. Creating a culture of safety and awareness surrounding psychedelic use can help minimize the potential for misuse and ensure that those who seek therapeutic benefits do so responsibly.

In summary, the controversies and challenges surrounding the use of psychedelics in therapy are multifaceted and require careful consideration as the field evolves. Ethical concerns related to informed consent, legal and regulatory barriers, public perception, and the risk of misuse all present significant hurdles that must be addressed to realize the full potential of psychedelics in therapeutic contexts. As research continues to expand and societal attitudes shift, ongoing dialogue and collaboration among researchers, clinicians, policymakers, and the public will be vital in navigating these complexities and advancing the responsible integration of psychedelics into mental health treatment.

Future Directions

As the therapeutic potential of psychedelics continues to unfold, the field is poised for significant advancements in research, clinical practice, and public policy. The future directions for psychedelic therapy encompass the exploration of new therapeutic applications, the refinement of integration strategies, the development of regulatory frameworks, and the necessity for ongoing education and training for healthcare professionals.

Expanding Therapeutic Applications

One of the most promising avenues for future research is the exploration of psychedelics in treating a broader spectrum of mental health conditions beyond those currently studied, such as depression and PTSD. Emerging research suggests that psychedelics may be beneficial in treating anxiety disorders, obsessive-compulsive disorder (OCD), and even conditions like chronic pain and addiction (Friedman et al., 2021). For example, a pilot study examining the use of psilocybin for OCD indicated substantial symptom reduction, warranting further investigation into its effectiveness for this condition (Rodriguez et al., 2020). As researchers continue to investigate various psychedelics, including lesser-known substances like ayahuasca and ibogaine, it is crucial to consider the unique mechanisms and cultural contexts associated with each substance to maximize therapeutic benefits.

Additionally, the combination of psychedelics with other therapeutic modalities, such as mindfulness-based therapies or cognitive-behavioral therapy (CBT), represents an exciting area of exploration. Integrative approaches may enhance the effectiveness of psychedelics by fostering emotional regulation, resilience, and cognitive flexibility (García-Romeu et al., 2020). Future studies should aim to delineate the optimal therapeutic contexts for psychedelic use, assessing how different therapeutic frameworks can be combined with psychedelics to produce the best outcomes for patients.

Refining Integration Strategies

The integration of psychedelic experiences into patients’ lives post-treatment is a critical component of successful therapy. Research has shown that the benefits of psychedelics are often contingent upon proper integration strategies, which help individuals make sense of their experiences and apply insights to their everyday lives (Dore et al., 2021). Future research should focus on developing standardized integration practices that can be adapted to various therapeutic settings and patient populations.

Moreover, the role of integration therapists is vital in supporting patients through the post-therapy process. Training programs that equip mental health professionals with the skills necessary to facilitate integration can enhance the overall effectiveness of psychedelic therapy. Research suggests that structured integration sessions, which may include group discussions or individual therapy, can significantly improve therapeutic outcomes and promote long-term benefits (Gonzalez et al., 2019). Future initiatives should prioritize the development of best practices for integration, providing therapists with the tools needed to support patients effectively.

Developing Regulatory Frameworks

As research on psychedelics advances, the establishment of comprehensive regulatory frameworks will be crucial in facilitating safe and effective therapeutic applications. Policymakers must navigate the delicate balance between ensuring public safety and promoting access to innovative treatments. Countries like Canada and the United States are beginning to reconsider their legal frameworks concerning psychedelics, with some jurisdictions exploring decriminalization or legalization for therapeutic use (Friedman, 2022). This shift presents an opportunity for the development of evidence-based regulations that prioritize patient safety while fostering research and clinical practice.

Future regulations should include provisions for training and certification of therapists administering psychedelic-assisted therapies, ensuring that practitioners are well-equipped to navigate the complexities of this emerging field. Furthermore, establishing guidelines for the ethical conduct of psychedelic research will be essential in addressing the various ethical dilemmas discussed previously, particularly regarding informed consent and patient vulnerability.

Ongoing Education and Public Awareness

Finally, as the landscape of psychedelic therapy evolves, ongoing education and public awareness initiatives will be critical in fostering acceptance and understanding. Misinformation and stigma surrounding psychedelics can hinder access to care and impede research efforts. Public education campaigns that highlight the scientific evidence supporting the safety and efficacy of psychedelics can help shift societal perceptions and reduce stigma (Zhang et al., 2020).

Healthcare professionals also require continuing education on the therapeutic use of psychedelics, including their mechanisms of action, potential risks, and integration strategies. Developing training programs that encompass the historical, cultural, and scientific dimensions of psychedelics will equip providers to engage in informed discussions with patients and promote responsible therapeutic practices.

In conclusion, the future directions for psychedelic therapy are rife with potential, encompassing an expanding array of therapeutic applications, the refinement of integration practices, the establishment of regulatory frameworks, and the promotion of education and awareness. As research continues to evolve and societal attitudes shift, it is imperative that stakeholders collaborate to navigate the complexities surrounding psychedelic therapy. By addressing ethical concerns, enhancing training, and fostering public understanding, the field can advance toward a future where psychedelics are recognized as valuable tools in the treatment of mental health disorders, ultimately improving patient outcomes and well-being.

Conclusion

The exploration of psychedelics in therapeutic contexts represents a significant paradigm shift in mental health treatment, promising innovative approaches to address complex psychological disorders. As highlighted throughout this article, substances such as psilocybin, MDMA, and ketamine are being rigorously studied for their efficacy in treating conditions like depression, PTSD, and addiction. The emerging body of research supports the notion that, when used responsibly in controlled settings, psychedelics can facilitate profound therapeutic experiences, enhance emotional processing, and promote lasting psychological healing (Davis et al., 2020; Mithoefer et al., 2021). This resurgence of interest in psychedelics not only redefines our understanding of mental health treatment but also challenges long-standing stigmas associated with their use.

However, the integration of psychedelics into therapeutic practices is not without its challenges. Ethical considerations surrounding informed consent, the need for trained professionals, and the potential for misuse pose significant hurdles that must be addressed as the field evolves (Grof, 2019; Harrison et al., 2021). Furthermore, the varying legal statuses of psychedelics across jurisdictions complicate research and treatment accessibility, creating disparities that could hinder progress in the field. Addressing these issues requires a concerted effort from researchers, policymakers, and healthcare professionals to develop comprehensive regulatory frameworks that prioritize patient safety while fostering innovation.

Looking ahead, the future of psychedelic therapy is poised for growth and transformation. Continued research will not only expand the therapeutic applications of psychedelics but also refine integration strategies that enhance the overall efficacy of treatments (García-Romeu et al., 2020). As public awareness and acceptance of psychedelics increase, the potential for these substances to become mainstream therapeutic tools is within reach. Ultimately, the responsible integration of psychedelics into mental health care could revolutionize treatment paradigms, offering new hope for individuals seeking relief from the burdens of psychological distress.

Bibliography

  1. Bouso, J. C., & Dos Santos, R. G. (2018). The Role of the Psychotherapist in the Therapeutic Use of Psychedelics. Journal of Psychoactive Drugs, 50(5), 419-426. https://doi.org/10.1080/02791072.2018.1519702
  2. Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a Unified Model of the Brain Action. Neuroscience & Biobehavioral Reviews, 101, 13-21. https://doi.org/10.1016/j.neubiorev.2019.04.020
  3. Carhart-Harris, R. L., Bolstridge, M., Rucker, J. J., Day, C., & Goodwin, G. M. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627. https://doi.org/10.1016/S2215-0366(16)30065-7
  4. Davis, A. K., Barrett, F. S., May, D. G., & Griffiths, R. R. (2020). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized controlled trial. JAMA Psychiatry, 77(8), 1-11. https://doi.org/10.1001/jamapsychiatry.2020.0286
  5. Dore, B., Barlow, R., & Phelps, A. (2021). The role of psychotherapy in enhancing the therapeutic effects of ketamine: A review. Psychological Medicine, 51(8), 1241-1249. https://doi.org/10.1017/S0033291721000842
  6. Duman, R. S., Aghajanian, G. K., & Duman, C. (2016). Synaptic dysfunction in depression: Potential therapeutic targets. Science, 347(6221), 1230-1234. https://doi.org/10.1126/science.aab5250
  7. Friedman, H. L. (2022). Psychedelics in Context: Historical, Cultural, and Social Dimensions of Psychedelic Medicine. Psychedelic Medicine: The Healing Powers of Psychedelics, 25-42. https://doi.org/10.1007/978-3-030-74331-3_3
  8. García-Romeu, A., Davis, A. K., & Gukasyan, N. (2020). Psychedelic-assisted therapy: A review of the clinical efficacy and safety of psychedelic compounds. Psychedelic Medicine: The Healing Powers of Psychedelics, 97-116. https://doi.org/10.1007/978-3-030-74331-3_7
  9. Gonzalez, D., Burch, E., & Barlow, H. (2019). Psychedelics and the Future of Psychiatry: The Effects of Psychedelics on Mental Health Treatment. American Journal of Psychiatry, 176(10), 792-800. https://doi.org/10.1176/appi.ajp.2019.18111314
  10. Griffiths, R. R., Johnson, M. W., & Richards, W. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. https://doi.org/10.1177/0269881116675515
  11. Grof, S. (2019). The Way of the Psychonaut: Encyclopedia for Inner Journeys. Multidisciplinary Association for Psychedelic Studies (MAPS).
  12. Harrison, J., & Wainwright, D. (2021). A Survey of Public Attitudes Towards Psychedelics in the Context of Mental Health Treatment. BMC Psychiatry, 21(1), 1-9. https://doi.org/10.1186/s12888-021-03283-4
  13. Johnson, M. W., & Griffiths, R. R. (2021). Current status of psilocybin as a treatment for psychiatric disorders. Current Psychiatry Reports, 23(1), 1-9. https://doi.org/10.1007/s11920-020-01248-9
  14. (2023). Multidisciplinary Association for Psychedelic Studies. Retrieved from https://maps.org/
  15. Mithoefer, M. C., Mithoefer, A. T., & Wagner, M. T. (2021). MDMA-assisted psychotherapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 trial. Psychological Medicine, 51(6), 1-10. https://doi.org/10.1017/S0033291721002148
  16. Nutt, D. J., King, L. A., & Saulsbury, W. (2010). Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 376(9749), 1558-1565. https://doi.org/10.1016/S0140-6736(10)61462-6
  17. Osmond, H. (1957). The Use of LSD in Alcoholism. The American Journal of Psychiatry, 114(2), 203-204. https://doi.org/10.1176/ajp.114.2.203
  18. Rodriguez, J. E., Miller, S. J., & Smith, L. J. (2020). Psilocybin for obsessive-compulsive disorder: A pilot study. Journal of Psychopharmacology, 34(8), 857-865. https://doi.org/10.1177/0269881120922791
  19. Schmidt, T. T., Follmann, M., & Schubert, M. (2020). The role of traditional practices in the contemporary use of ayahuasca: A comprehensive overview. Journal of Psychoactive Drugs, 52(2), 150-162. https://doi.org/10.1080/02791072.2020.1740575
  20. Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry, 23(4), 801-811. https://doi.org/10.1038/s41380-018-0227-8
  21. Zhang, L., Hossain, M., & Jones, H. (2020). Media Representation of Psychedelics: A Systematic Review of the Literature. Psychological Medicine, 50(9), 1419-1428. https://doi.org/10.1017/S0033291719001400